Volume 11, Number 4—April 2005
Dispatch
Human Spotted Fever Rickettsial Infections
George B. Schoeler*1, Cecilia Morón†, Allen L. Richards‡, Patrick J. Blair§, and James G. Olson§
Table 1
EIA and IFA test results for antibodies to Rickettsia rickettsii among patients from 4 areas of Peru*
| Department | EIA |
IFA |
EIA and/or IFA |
|||
|---|---|---|---|---|---|---|
| No. tested† | No. positive (%)‡ | No. tested† | No. positive (%)§ | No. tested† | No. positive (%) | |
| Cusco | 36 | 6 (17) | 56 | 11 (20) | 67 | 16 (24) |
| Junin | 42 | 8 (19) | 19 | 2 (11) | 53 | 10 (19) |
| Piura | 50 | 4 (8) | 0 | 50 | 4 (8) | |
| Total | 128 | 18 (14) | 75 | 13 (17) | 170 | 30 (18) |
*By enzyme immunoassay (EIA) or indirect immunofluorescence antibody assay (IFA).
†Febrile patients from whom acute- and convalescent-phase serum specimens were available for testing.
‡Criterion for confirmation was a ≥4-fold increase in R. rickettsii immunoglobulin (Ig) G antibody titer from acute to convalescent phase of illness by EIA.
§Criterion for confirmation was a ≥4-fold increase in R. rickettsii IgG antibody titer from acute to convalescent phase of illness by IFA.
Page created: May 23, 2011
Page updated: May 23, 2011
Page reviewed: May 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.